Atogepant (Qulipta)

How Medicare covers it

Part D (forms used at home). Part A during a covered inpatient stay. No Part B clinician-administered form in the CMS Part B spending file.

What it treats

Migraine prevention in adults — Qulipta is taken every day to reduce how often migraines happen, for both episodic migraine (fewer headache days) and chronic migraine (very frequent headache days). It does not stop a migraine that has already started.

What it is for, in depth

Atogepant (Qulipta) is a daily preventive migraine medicine for adults. It is prescribed for people whose migraines come often enough that prevention — not just treating each attack — makes sense: episodic migraine at 10, 30, or 60 mg once daily, and chronic migraine at 60 mg once daily. It belongs to the CGRP family of migraine preventives, and it is the oral daily-tablet option in that family (others are monthly injections). It is a first preventive choice for many patients rather than an add-on of last resort, and the label supports starting it directly for prevention. Forms: 10 mg, 30 mg, and 60 mg tablets, taken once a day with or without food.

How it works

Atogepant blocks the CGRP receptor. CGRP is a protein involved in migraine attacks; blocking its receptor helps prevent migraines from starting.

How it is taken

It is a tablet taken by mouth once a day, with or without food. For episodic migraine the dose is 10 mg, 30 mg, or 60 mg once daily; for chronic migraine it is 60 mg once daily. Tablets come in 10 mg, 30 mg, and 60 mg strengths.

Common side effects

The label's clinically significant adverse reactions are allergic (hypersensitivity) reactions, new or worsening high blood pressure, and Raynaud's phenomenon (fingers or toes turning pale or blue from reduced blood flow). In the full label's trial data, nausea, constipation, and tiredness were also among the most common effects.

Serious warnings

Serious allergic reactions, including anaphylaxis (a life-threatening allergic reaction) and trouble breathing, have happened and can occur days after a dose — stop the drug and get treatment right away if one occurs. New-onset or worsening high blood pressure may occur, and Raynaud's phenomenon may start or get worse.

Who should be careful

Anyone who has had an allergic reaction to atogepant or any Qulipta ingredient must not take it. People with severe kidney disease or kidney failure should take only 10 mg once daily for episodic migraine, and it is not recommended for their chronic migraine. It should be avoided in severe liver impairment. Based on animal data, it may cause fetal harm in pregnancy.

Major interactions

Strong CYP3A4 inhibitors (drugs that block a liver enzyme, such as certain antifungals and antibiotics) require lowering Qulipta to 10 mg once daily. Strong CYP3A4 inducers require 60 mg once daily for episodic migraine and make it not recommended for chronic migraine. OATP inhibitor drugs also require lower doses, as the label's dose-modification table states.

Cost and saving notes

Qulipta is a brand-name drug with no generic version in this label. If your Medicare Part D plan places it on a high tier, you can ask the plan for a tier exception, and if you have low income you may qualify for Extra Help (the Low-Income Subsidy), which lowers Part D premiums and drug costs.

Why it is in its tier

Atogepant (Qulipta) sits on Tier 3 in 62.76% of the plans that list it (2130 of 3394 listing plans). Tier 3 is the preferred brand tier — mid-level copays or coinsurance. The data-visible drivers: It is a brand-only product with no generic version in the formulary data, and the CMS dashboard puts its average Part D spending at about $5,779 per beneficiary for 2024 — a high-cost drug, which matches where plans place it. It is listed by 61.77% of Part D plans. The tier shown is the most common one; individual plans vary.

Sources

• QULIPTA (ATOGEPANT) TABLET [ABBVIE INC.] — DailyMed
• MedlinePlus — National Library of Medicine
• MedlinePlus — Atogepant

What official patient guides say

Atogepant comes as a tablet you take by mouth once a day, with or without food, at around the same time every day. If you miss a dose, take it as soon as you remember it, but if it is almost time for the next dose, skip the missed dose and go back to your regular schedule — do not take a double dose to make up for one you missed. Keep all of the medicine out of the sight and reach of children, always lock the safety cap, and store it in a safe place that is up and away where children cannot see or reach it. When you no longer need the medicine, take it to a medicine take-back program so that pets, children, and other people cannot get to it, and do not flush it down the toilet.

Source: MedlinePlus — Atogepant

Part D formulary coverage

Source: CMS Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files — Monthly file 2026-10-15 (plan year 2027), file 2027_20261008.zip (data.cms.gov dataset ed1496ea-23e7-41f1-9292-172fa842ccfb): basic drugs formulary file + plan information file, both dated 20261031 inside the zip; downloaded and aggregated 2026-10-30. Medication RxCUI sets resolved through the NLM RxNav (RxNorm) API.

What you pay

Without insurance, the cash benchmark is 38.34545 per unit (QULIPTA 10 MG TABLET) — about nan for 30 units. NADAC benchmark — the average price pharmacies pay (CMS, as of 2026-11-04). Pharmacy shelf prices vary.

A tier is not a price; what you pay depends on your plan, pharmacy, and benefit stage; Extra Help or Medicaid can lower it further.

Sources: CMS Plan Benefit Package + formulary data; CMS NADAC · Checked 2026-11-07

Coverage by plan and tier

Of the 5,495 Medicare drug plans we track for 2027, 3,394 list Atogepant (Qulipta) — 61.8% of plans. Most of those plans put it on Tier 3: 2,130 plans, 62.8% of the plans that list it. Other plans place it on Tier 4 (951 plans), Tier 5 (210 plans) or Tier 1 (95 plans). For example: Aetna Medicare Dual Extra (HMO D-SNP) puts it on Tier 3; Aetna Medicare Dual Extra Care (PPO D-SNP) puts it on Tier 3; Aetna Medicare Value Plus (PPO) puts it on Tier 3. You can compare these plans side by side on our Medicare Advantage hub. A tier is not a price. What you pay also depends on whether you have met your plan';s deductible, whether the drug costs a flat copay or a share of the price, and whether you get Extra Help or Medicaid.

Read next

• Part D in 2027: The $700 Deductible, the $2,400 Cap, and the $35 Insulin Rule
• Extra Help in 2027: Lower Drug Copays and Who Qualifies
• Checking Medicare Savings Programs and Extra Help

Part D spending averages (2024)

Source: CMS Medicare Part D Spending by Drug (Drug Spending Dashboard), release RY26 P04 V10, data through 2024 (DSD_PTD_RY26_P04_V10_DY24_BGM.csv), downloaded 2026-10-30

Companies covering this drug

Part D and Medicare Advantage plan sponsors that list this drug on a formulary, 50 at a time.